The Federation of Japan Pharmaceutical Wholesalers Association (JPWA) on December 6 leaned on policymakers to create a permanent mechanism to continuously prop up the prices of medically essential drugs, beyond a transient measure at a time of emergencies.JPWA Chairman Hiromi…
BUSINESS
Lilly Japan Set for Leading Spot in All Core Areas in 2025, “No Plan to Replicate” Redundancy Program: Chief
Eli Lilly Japan aims to be a leading company in all of its five key strategic areas by 2025, anticipating an “unprecedented number” of new drug approvals and indications coming over the next five years, President Simone Thomsen told Jiho…
To read the full story
Related Article
- Lilly Japan Suffers Negative Growth for 3rd Straight Year in 2022 as 2 Major LOEs Weigh
April 26, 2023
- Innovative Brands to Drive Return to Growth at Lilly Japan after 2 Years of Decline: President
April 13, 2022
- Lilly Japan Chief Sees Continued Diabetes Investment as Key to Remaining in Top 10
June 22, 2020
- Lilly Expects Topline Data for 2 COVID-19 Drug Candidates by June-End, First Patient Dosed in Antibody Treatment Study: Japan Execs
June 3, 2020
BUSINESS
- KM, Meiji Initiate PIII Pediatric Trial for XBB.1.5-Adapted COVID Vaccine
December 8, 2023
- Pivlaz Approved in South Korea, Set for Launch in Early 2025
December 8, 2023
- Japan Ethical Drug Sales Up 8.4% in October: Crecon
December 8, 2023
- Keytruda Scores No. 1 in Japan Sales Ranking in November: Encise
December 8, 2023
- Daiichi Sankyo, Novartis Settle Patent Infringement Dispute Over Tafinlar
December 7, 2023
Referrals can be an absolute game-changer in recruitment.When someone in your network recommends a candidate, they often have firsthand insight into the person’s skills, work ethic, values and ambitions. This insider knowledge results in higher quality candidates who are a…
Chugai Pharmaceutical’s Phesgo (pertuzumab + trastuzumab + vorhyaluronidase alfa) and Novartis’ Leqvio (inclisiran) will be newly added to the Japanese reimbursement list along with a batch of other medicines on November 22. Three drugs carry peak sales outlooks of over…
The main players in the FY2024 reimbursement policy reform are now all in place, with the roster rounded out by the appointment of former health minister Katsunobu Kato for the Liberal Democratic Party’s (LDP) prominent social security post at the…
A member of the Ministry of Health, Labor and Welfare’s (MHLW) study group on the generic industry on November 13…
A health ministry study group on pharmaceutical regulations on October 13 roughly agreed on a reform plan for Japanese regulatory…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…
A key Japanese reimbursement policy panel on December 16 approved the government-backed plan for the FY2023 “off-year” drug price revision.…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…